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Background: Recombinant soluble, cleaved HIV-1 envelope glycoprotein SOSIP.664 gp140 trimers based on the
subtype A BG505 sequence are being studied structurally and tested as immunogens in animals. For these trimers to
become a vaccine candidate for human trials, they would need to be made in appropriate amounts at an acceptable
quality. Accomplishing such tasks by transient transfection is likely to be challenging. The traditional way to express
recombinant proteins in large amounts is via a permanent cell line, usually of mammalian origin. Making cell lines that
produce BG505 SOSIP.664 trimers requires the co-expression of the Furin protease to ensure that the cleavage site
between the gp120 and gp41 subunits is fully utilized.
Results: We designed a vector capable of expressing Env and Furin, and used it to create Stable 293 T and CHO
Flp-In™ cell lines through site-specific recombination. Both lines produce high quality, cleaved trimers at yields of up to
12–15 mg per 1 × 109 cells. Trimer expression at such levels was maintained for up to 30 days (10 passages) after initial
seeding and was consistently superior to what could be achieved by transient transfection. Electron microscopy studies
confirm that the purified trimers have the same native-like appearance as those derived by transient transfection and
used to generate high-resolution structures. They also have appropriate antigenic properties, including the presentation
of the quaternary epitope for the broadly neutralizing antibody PGT145.
Conclusions: The BG505 SOSIP.664 trimer-expressing cell lines yield proteins of an appropriate quality for structural
studies and animal immunogenicity experiments. The methodology is suitable for making similar lines under Good
Manufacturing Practice conditions, to produce trimers for human clinical trials. Moreover, any env gene can be
incorporated into this vector system, allowing the manufacture of SOSIP trimers from multiple genotypes, either by
transient transfection or from stable cell lines.
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The development of a vaccine against HIV-1 infection
remains a significant global health problem. One of the
major vaccine design concepts is the induction of high
titer broadly neutralizing antibodies (bNAbs) that are cap-
able of preventing HIV-1 entry into its target cells, and* Correspondence: jpm2003@med.cornell.edu; alc2028@med.cornell.edu
†Equal contributors
1Department of Microbiology and Immunology, Weill Cornell Medical
College, New York, NY, USA
Full list of author information is available at the end of the article
© 2014 Chung et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.hence intervening against virus transmission [1]. The only
relevant target for bNAbs is the Env complex, or spike, on
the virus surface [2,3]. This complex, a trimer of gp120/
gp41 heterodimers, attaches to receptors on target cells
and then mediates fusion of the viral and cell membranes
[4]. Any antibodies that can bind to a sufficient number of
functional Env spikes will impede one or more stages in
the receptor-binding and fusion process, thereby neutral-
izing infectivity [2].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Among relevant strategies is the creation of structural and
antigenic mimics of the native, virion-associated Env spike.
To do so involves inserting a stop codon to truncate the
gp140 prior to the membrane-spanning domain, thereby
yielding soluble proteins that can be secreted from produ-
cer cells and purified. Unfortunately, without suitable se-
quence modifications, soluble gp140s are highly unstable
and either disintegrate completely into their constituents
or adopt non-native configurations that may be compro-
mised from the perspective of bNAb induction [5,6]. One
effective strategy for making soluble, native-like trimers
involves introducing a disulfide bond (designated SOS)
to link the gp120 and gp41 ectodomain (gp41ECTO) com-
ponents, combined with a point substitution (I559P) in
gp41ECTO that creates additional stability [7-9]. Proteolytic
cleavage between the gp120 and gp41 subunits is also
critical for making native-like trimers, and is facilitated
by optimizing the cleavage site and co-expressing the
Furin protease [8,9]. At present, the most advanced sol-
uble, cleaved trimers, based on a subtype A founder
virus, are designated BG505 SOSIP.664 [10-12]. These
highly homogeneous trimers closely resemble virus spikes
when visualized by negative stain electron microscopy (EM)
[10]. They also have highly favorable antigenic properties,
expressing multiple bNAb epitopes while occluding most
epitopes for non-neutralizing antibodies (non-NAbs) [6,10].
In addition, the structure of these trimers has been deter-
mined by both x-ray diffraction and cryo-EM at ~5-6 Å
resolution [13,14]. Animal immunogenicity studies are in
progress.
To facilitate the production of BG505 SOSIP.664 gp140
trimers as pre-clinical research reagents, and to establish a
proof-of-concept for their future manufacture as clinical-
grade immunogens, we have assessed whether they can be
expressed in permanent cell lines. A complexity in the cell
line design strategy was the need to co-express Furin, to
ensure the trimers are fully cleaved. Another important
requirement for a stable mammalian cell line is a defined
integration site(s). The Flp-In™ system seemed an appro-
priate choice; it has, for example, been used to produce in-
fluenza hemagglutinin-based vaccines [15]. Here, we show
that the Flp-In™ method can be used to make both 293 T
and CHO cell lines that yield substantial amounts (up to
12–15 mg from 1 × 109 cells) of high quality trimers. The
purified trimers are fully cleaved, have appropriate anti-
genic properties and, when viewed by negative stain EM,
appear identical to ones produced by transient transfec-
tion [6,10]. The method used to make the lines is speedy
and flexible, which will facilitate the future production
of additional SOSIP trimers of improved designs and/or
different genotypes. It should also be adaptable to Good
Manufacturing Practice (GMP) conditions appropriate
for making immunogens for human vaccine trials.Results
Design of pAM/C BG505 vector expressing BG505
SOSIP.664 gp140 and Furin
The pcDNA5/FRT vector contains multiple promoters
and polyadenylation sites [16]. The choice of elements
to use in the pAM/C BG505 vector was determined by
assessing the priority of expression. Thus, we elected to
use the highest activity (CMV) promoter for Env expres-
sion (to maximize trimer production), but a lower activ-
ity promoter (EFI Alpha) for Furin (to reduce the risk of
cytotoxicity). When choosing the promoters and polya-
denylation sites, we also considered the elements already
present within the pcDNA5/FRT vector. For example,
we could not use the SV40 promoter and Poly A for ex-
pressing Env or Furin because these elements are already
active in the vector. Overall, we decided that the most
efficient additions to the pcDNA5/FRT vector would be
the EF1 Alpha promoter and a synthetic Poly A from
New England BioLabs (modeled from the HSV Thymi-
dine Kinase Poly A), between the HindIII and NotI clon-
ing sites (Figure 1A).
A Flp Recombination Target (FRT) site in the pcDNA5/
FRT vector is linked to the hygromycin-resistance gene,
which allows for Flp recombinase-mediated integration
and the selection of a stable cell line. The complete BG505
SOSIP.664 gp140 sequence was cloned into pcDNA5/FRT
between the HindIII and NotI sites, under the control of
the CMV promoter to promote high-level constitutive Env
expression (Figure 1A). Since complete cleavage of Env at
the gp120-gp41ECTO juncture is essential for the produc-
tion of native-like trimers [5,6,9,17] we also inserted the
furin gene, in this case under the control of the weaker EFI
Alpha promoter. The resulting plasmid that contains both
the BG505 SOSIP.664 gp140 and Furin sequences is desig-
nated pAM/C BG505 (Figure 1A).
Selection and propagation of Stable 293 T and CHO cell
lines expressing BG505 SOSIP.664 gp140
The pAM/C BG505 vector was co-transfected with vector
pOG44, which encodes the Flp recombinase that mediates
integration of the pcDNA5/FRT vector into the FRT site
of Flp-In™ cells. Using the Flp-In™ system, we obtained
four potentially stable preliminary cell lines, 293 T lines
13 and 15 and CHO lines A and B. To eliminate the possi-
bility that these initial lines were non-isogenic (i.e., genet-
ically mixed), we next performed limiting dilution on the
293 T Flp-In™ line 13 and the CHO lines A and B, as these
three consistently expressed the highest Env levels judged
by dot blot using MAb 2G12. Limiting dilution resulted in
32 potential 293 T cell clones and 10 potential CHO cell
clones. We used FITC-labeled MAb 2G12 (FITC-2G12)
and FACS to assess Env expression and clonality; this
procedure identified 293 T clone 13 #3-5 and CHO
clone B-D7 as the highest-expressing clones for further
Figure 1 (See legend on next page.)
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Figure 1 Vector for constitutive secretion of BG505 SOSIP.664 gp140 in a Flp-In™ based expression system, and stable cell line selection.
(A) Design of the pAM/C construct for expressing BG505 SOSIP.664 gp140. The plasmid map shows the site of the env and furin gene insertions, the
promoters and the Poly A sequences. (B) Intracellular Env expression in transfected 293 T and CHO cells. The histograms represent parental cells (red)
and stable cell clones (blue); the numbers (top right of each panel) are the mean fluorescence intensity (MFI) values after staining with FITC-2G12.
(C) Secretion of BG505 SOSIP.664 gp140 trimers by Stable 293 T and CHO cell clones. The trimer concentrations in the culture supernatants were
determined by ELISA using 2G12 and bio-PGT145. (D) Fluorescent microscopy of stable cell clones. Cells were grown in an 8-well chamber slide,
treated with Brefeldin A, fixed, permeabilized and stained for Env (FITC-2G12; green) or nuclear DNA (DAPI; blue). The left panels show parental 293 T
and CHO cells, the right, the stable cell clones.
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based on 2G12 capture of Env proteins followed by
detection of trimers with biotinylated MAb PGT145
(bio-PGT145) confirmed that culture supernatants from
these clones contained the highest quantities of trimers:
2.1 μg/ml for 293 T clone 13 #3-5 and 1.7 μg/ml for CHO
clone B-D7 (Figure 1C). Staining with FITC-2G12 in the
presence of Brefeldin A showed that Env proteins accu-
mulated within the cell for both these clones, but were
absent from the parental controls (Figure 1D).
Sustained intracellular Env expression in Stable 293 T and
CHO cell lines
After initial seeding, approximately constant levels of intra-
cellular Env were detected during ten subsequent passages
(P1-10, one passage every 4 days) of the 293 T clone
13 #3-5 and the CHO clone B-D7. Both lines are there-
fore stable and not prone to genetic instability (Figure 2A).
The production of BG505 SOSIP.664 gp140 trimers, as
judged by ELISA, was also steady over time during pas-
sages 1 through 10, with yields in the range of 2 and
3 μg/ml of supernatant for the 293 T and CHO cell clones,
respectively (Figure 2B). Cell viability (parental vs. stable
cell lines) was 91-98% vs. 91-96% for 293 T, and 86-95% vs.
87-94% for CHO, throughout the culture period, implying
that neither Env nor Furin was cytotoxic to these lines
(Figure 2C). Overall, the two stable cell lines could be pas-
saged for 5 weeks without any observable reduction in
Env expression or cell viability. The BG505 SOSIP.664 tri-
mers can, therefore, be produced by the same batch of
cells for at least this period after initial seeding, and prob-
ably far longer.
Biochemical characterization of BG505 SOSIP.664 trimers
from 293 T and CHO stable cell lines
We next assessed the quantity and quality of the trimers
produced by the stable cell lines, in comparison with
transiently transfected 293 T and CHO cells. In all cases,
the trimers were purified by 2G12-affinity chromatog-
raphy followed by size exclusion chromatography (SEC)
[6,10]. A Coomassie blue-stained native (BN-PAGE) gel
showed that the 2G12-enriched Env proteins were mostly
trimeric, with only modest amounts of dimers and/ormonomers visible (Figure 3A). The trimer fractions were
then purified by SEC. Gel-electrophoretic analyses under
native conditions (BN-PAGE, followed by Coomassie blue
staining) showed that the purities of the different trimer
preparations (cell lines vs. transient transfection) were in-
distinguishable (Figure 3B). The CHO cell-derived trimers
migrated slightly more quickly than their 293 T counter-
parts, probably reflecting subtle, cell-dependent differences
in glycan profiles that affect mobility during electrophoresis
(Figure 3B).
The yield of purified trimers from the 293 T stable cell
line was 12 mg (range 10–15 mg) per 1 × 109 cells, which is
10-fold greater than when the same number of 293 T cells
were transiently transfected (range 1.25-1.5 mg) (Table 1).
For the stable CHO cell line vs. transiently transfected
CHO cells, the corresponding values were 12 mg (range
10–15 mg) and 0.375 mg (range 0.25-0.5 mg), a ~32-fold
differential.
The various SEC-purified BG505 SOSIP.664 trimer
preparations were fully cleaved. Thus, when the reducing
agent dithiothreitol (DTT) was included in SDS-PAGE
gels, the gp140 proteins dissociated into their gp120 and
gp41ECTO subunits (Figure 3C). Note that the gp41ECTO
fragments stain poorly and are not always visible.
We next analyzed the purified trimers on a reducing
SDS-PAGE gel followed by western blotting, with the goal
of identifying whether any proteolytic degradation events
occur during production or purification (Figure 3D). The
detection MAb, ARP 3119, binds to a well-conserved,
linear epitope within the N-terminal half of gp120. In
other studies, we confirmed that it recognizes the 70-kDa
(but not the 50-kDa) fragment that is produced when
monomeric MN gp120 is clipped by proteases within the
V3 region (data not shown). When the BG505 SOSIP.664
trimer blots were probed with ARP 3119, only a 120-kDa
band (i.e., gp120) was detected, with no degradation prod-
ucts visible (Figure 3D). To seek any Env fragments that
might escape detection by ARP 3119, we performed a
similar reducing SDS-PAGE and Western blotting analysis
but probed the blots with polyclonal HIV-Ig (Figures 3E
and F). As positive controls, we included two other
types of Env protein that are known to be vulnerable to
proteolytic degradation, i.e., a monomeric gp120 and an
Figure 2 Sustained expression of BG505 SOSIP.664 gp140 by stable cell lines. (A) Intracellular Env expression with continued passage of
the 293 T 13# 3–5 and CHO B-D7 stable cell lines (blue curves). The fixed and permeabilized cells were stained with FITC-2G12 (20 μg/ml) after
culture for 6 h in the presence of Brefeldin A. MFI values for the Env-expressing clones are recorded in the top right corner of each histogram.
Parental cells served as negative controls (red curves show MFI values: ranges 9.12-12.9 for 293 T cells and 7.23-13.2 for CHO cells). (B) Production
of BG505 SOSIP.664 gp140 trimers by the stable cell lines throughout the culture period, as determined by ELISA using 2G12 and bio-PGT145.
(C) Viability of stable cell clones during passage. The cells were stained with trypan blue, with the percentage of viable cells (parental vs. stable)
shown as the passage number increases.
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gp41ECTO subunits [5,6,18,19]. The BG505 SOSIP.664
trimers are from subtype A, the gp120 protein, MN, is
from subtype B, and the uncleaved gp140, CZA97.012,
from subtype C [20]. Accordingly, we used a HIV-Ig pool
based on sera from different individuals infected with vi-
ruses from all three subtypes. The comparator gp120 and
gp140 proteins were SEC-purified and each migrated as asingle band of appropriate size when analyzed by BN-PAGE
and Coomassie blue staining (data not shown).
The Coomassie blue-stained, reducing SDS-PAGE gel
again revealed no degradation products of the BG505
SOSIP.664 trimers; the major band corresponds to the
gp120 subunit and a less well stained, smaller band is the
gp41ECTO moiety. In contrast, multiple degradation prod-
ucts were clearly visible in the SEC-purified monomeric
Figure 3 Biochemical characterization of cell line-derived BG505 SOSIP.664 gp140 trimers and comparator proteins. (A) BN-PAGE
analysis of 2G12-purified Env proteins produced by the BG505 SOSIP.664-expressing 293 T and CHO stable cell lines. The gels were stained with
Coomassie blue. The molecular weights of marker (M) proteins (thyroglobulin, 669 kDa and ferritin, 440 kDa) are indicated. (B) A similar BN-PAGE
analysis, but of SEC-purified trimers. (C) SDS-PAGE analysis of SEC-purified BG505 SOSIP.664 trimers, under non-reducing (− DTT) and reducing
(+ DTT) conditions, followed by Coomassie blue staining. Cleavage of gp120 from gp41ECTO is assessed by the conversion of the gp140 band to
gp120 in the presence of DTT; the released gp41ECTO subunit is not always stained strongly. (D) Western blot analysis of a reducing SDS-PAGE gel
to assess the quality of SEC-purified BG505 SOSIP.664 trimers. The blots were probed with the anti-gp120 MAb, ARP 3119. No Env degradation
products arising from V3-clipping or other proteolysis events are visible. (E) Reducing SDS-PAGE analysis of SEC-purified BG505 SOSIP.664 trimers
and comparator Env proteins, followed by Coomassie blue staining. The comparator proteins were also SEC-purified to yield the 120-kDa fraction
for MN gp120 and the “trimer” fraction (i.e., proteins containing three gp120 and three gp41ECTO subunits) for uncleaved CZA97.012 gp140.
Multiple degradation and/or aggregation products derived from MN gp120 and CZA97.012 gp140 are visible, but none from the BG505 SOSIP.664
trimers. (F) Western blot analysis of the same gel shown in (E). The detection antibodies were a pool (1:1:1) of polyclonal HIV-Igs derived from
subtype A, B and C infections. The various aggregates or degradation products seen in (E) are Env-based.
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bands from the gp120 monomers were the characteristic
70 kDa and 50 kDa fragments arising from V3 clipping.However, additional, unknown fragments of the uncleaved
gp140 were also present, as well as high m.wt. bands cor-
responding to proteins that spontaneously aggregate after
Table 1 Production of BG505 SOSIP.664 gp140 trimers by
stable cell lines relative to transiently transfected cells
Production system Purified trimer yield per 1 × 109 cells
CHO PEI transfection 0.25-0.5 mg
CHO stable cell line 10-15 mg
293 T PEI transfection 1.25-1.5 mg
293 T stable cell line 10-15 mg
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inforced by Western blots, which confirmed that the vari-
ous additional gp120- or gp140-derived bands were Env
proteins. Again, however, there were no signs of degrad-
ation or aggregation with the various cell sources of BG505
SOSIP.664 trimers (Figure 3F).Surface plasmon resonance and ELISA analysis of BG505
SOSIP.664 gp140 trimers produced from Stable 293 T and
CHO cell lines
The trimers produced by the permanent cell lines do not
contain D7324-epitope or His-tags, which precludes as-
sessment of their antigenicity by the SPR and capture
ELISA methods for tagged trimers that we have previously
described [6,10]. We therefore devised SPR and ELISA
methods suitable for use with non-tagged trimers derived
from both the permanent 293 T and CHO cell lines and,
for comparison, made by transient transfection.
For SPR, we immobilized anti-Env MAbs on CM5 chips
and flowed the purified BG505 SOSIP.664 trimers over
them, recording binding as the response difference (RU).
Immobilized bNAb PGT145, to a quaternary structure-
dependent (i.e., trimer-specific) epitope, bound strongly
while, in contrast, the non-NAb F105 against a CD4bs epi-
tope reacted only minimally (Figure 4A). The F105 epitope
is occluded on native trimers [10,21]. We have reported
elsewhere that this MAb binds efficiently to BG505 gp120
monomers, and also to uncleaved (i.e., non-native) BG505
gp140 proteins [6,10]. Accordingly, the lack of F105 re-
activity with the purified BG505 SOSIP.664 trimers is con-
sistent with the absence of contaminant gp120 monomers
of other non-native forms of Env such as uncleaved gp140
proteins. Of note is that the binding profiles obtained for
the two MAbs were independent of the cell source of the
trimers (Figure 4A).
The ELISA format involved trimer capture to the solid
phase via the absorbed bNAb 2G12, followed by detection
using biotin-labeled versions of the same PGT145 or F105
MAbs. As with the SPR system, an appropriate measure
of structural authenticity for the trimers is strong PGT145
reactivity combined with low binding of F105. Again, irre-
spective of the trimer source, we found that PGT145 bound
efficiently in the 2G12-capture ELISA whereas F105 was
completely non-reactive (Figure 4B).Electron microscopy imaging of BG505 SOSIP.664 gp140
trimers produced from stable 293 T and CHO cell lines
The different preparations of purified trimers were viewed
by negative-stain EM, and the reference-free 2D class av-
erages were examined to determine their overall morph-
ology. The trimers from both cell lines had the same
consistently native-like appearance as those derived by
transient transfection (Figure 5A) [10]. The percentages of
native-like trimers varied in the range 81-100%, and were
usually somewhat higher for 293 T cell-derived trimers
(90-100%) than CHO (80-90%). However, we consider that
native-like trimer percentages in this range (80-100%) are
within experimental error for this method. Accordingly,
we conclude that trimers from both the 293 T and CHO
stable lines adopt a single native-like configuration that is
indistinguishable, at this level of resolution, from the tran-
sient transfection products used to derive high-resolution
cryo-EM and X-ray structures [13,14].
In a differential scanning calorimetry (DSC) assay, tri-
mers produced in the Stable 293 T and CHO cell lines
underwent a single, sharp thermal transition at 66.9°C and
66.3°C, respectively (Figure 5B). These values are compar-
able to those of 68.1°C for trimers produced by transient
transfection of 293 T cells [10], and 67.9°C for ones made
by transient transfection of 293S cells [22]. Overall, the
DSC data further confirm the homogeneity of the different
trimer preparations.
Discussion
Here, we describe the production and properties of stable
lines, derived on 293 T and CHO cell backgrounds, which
express soluble, cleaved BG505 SOSIP.664 gp140 trimers.
The 293 T and CHO lines each produced trimers at
acceptable levels, with final yields after SEC purification
of 10 mg and 12 mg per 1 × 109 cells, respectively. The cell
lines, of course, produce trimers continuously. Accord-
ingly, we estimate that, under standard laboratory con-
ditions, we can generate 20–40 mg of trimers from 10
fully confluent seeded hyperflasks, by re-feeding media and
harvesting ~12-24 liters of supernatant over a 2–3 week
period.
The purified BG505 SOSIP.664 gp140 trimers appear
indistinguishable from ones produced by transient trans-
fection of the same cell types, as judged by biochemical,
antigenicity, EM and DSC analyses [10,22,23]. The cell
line-derived trimers were fully cleaved, as determined by
SDS-PAGE under reducing vs. non-reducing conditions
(Figure 3C). The negative stain EM images and the antige-
nicity profiles are also completely consistent with efficient
trimer cleavage, as uncleaved gp140 proteins have dif-
ferent antigenicity properties (i.e., F105-reactive, PGT145-
nonreactive) and a distinctive, non-native appearance when
viewed by EM [6]. The 293 T and CHO cell-derived tri-
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Figure 4 Antigenicity of cell line-derived BG505 SOSIP.664 gp140 trimers. (A) SPR sensorgrams for the PGT145 bNAb and the F105 non-NAb.
Each MAb was captured onto the chip by an immobilized anti-Fc Ab, and the binding of BG505 SOSIP.664 gp140 trimers (200 nM) from the various cell
sources was recorded as response difference (RU) after background correction: PGT145 bound strongly and similarly to the trimers of different origin,
but F105 binding was undetectable. Each curve represents one of two similar replicates. (B) Representative binding curves in the 2G12-capture ELISA
for the same PGT145 bNAb and F105 non-NAb to BG505 SOSIP.664 gp140 trimers from the various cell sources. The plotted OD values have been
background corrected (i.e., with no gp120 present). Similar data were obtained in three experiments of the same design.
Chung et al. Retrovirology 2014, 11:33 Page 8 of 14
http://www.retrovirology.com/content/11/1/33immunogenicity studies. They may differ in the fine details
of their glycosylation, given that the cells are of human
and hamster origin, respectively. We have not, however,
yet found any antigenic differences between 293 T- and
CHO-cell derived trimers (with or without ELISA-enabling
epitope tags), including with multiple bNAbs to glycan-
dependent epitopes (Figure 4, and data not shown). Hence
both cell lines are likely to be useful resources for trimer
production. Of note is that BG505 SOSIP.664 gp140
trimers produced by transient transfection of 293 T and
293S cells were the reagents used to generate cryo-EM
and x-ray structures, respectively, at ~5-6 Å resolution[13,14]. We are now making good progress towards a per-
manent cell line based on 293S cells, for additional x-ray
diffraction studies.
We saw no indications that the cell line-derived BG505
SOSIP.664 trimers are degraded by proteases, including
but not limited to ones that clip the V3 region to yield
characteristic 70 kDa and 50 kDa fragments on reducing
SDS-PAGE gels and Western blots (Figure 3D-F) [18,19].
In contrast, a monomeric gp120 (MN) and an uncleaved
gp140 (CZA97.012) were highly vulnerable to proteolytic
degradation, including but in the latter case not limited to
V3 clipping. The uncleaved gp140 also formed aggregates
Figure 5 Negative stain EM images and DSC traces for BG505 SOSIP.664 gp140 trimers produced by 293 T and CHO cells. (A) Reference-free
2D class averages are shown for trimers from transiently transfected or Stable 293 T and CHO cell lines, as indicated. (B) Thermal denaturation profiles
of BG505 SODSIP.664 trimers from the 293 T (left panel) and CHO stable cell lines (right panel).
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three gp41ECTO subunits was first SEC-purified (Figure 3E
and F). The resistance of the BG505 SOSIP.664 trimers
to proteolytic degradation is at least partly because the
BG505 V3 sequence is not particularly vulnerable to
clipping, compared to other Env genotypes; we have, for
example, seen no signs of V3 clipping when making mono-
meric BG505 gp120 proteins by transient transfection
when, under the same conditions, MN gp120 is badly de-
graded (data not shown). However, there are also structural
considerations; the SOSIP.664 trimers are compact entities
in which potentially vulnerable scissile sites, particularly
V3, are inaccessible to proteases [13,14]. We have also not
observed V3 clipping or other signs of gp120 degradationwith other SOSIP.664 trimers, including ones based on sub-
type B sequences (AC, JK and JPM, unpublished results). In
contrast, V3 and other protease-sensitive regions are more
exposed on both gp120 monomers and uncleaved gp140s.
The latter invariably adopt splayed out, non-native shapes
with three individual gp120 subunits dangling freely from a
central gp41ECTO 6-helix-bundle, conformations in which
various sites, including V3, are exposed to protease attack
[5,6]. In addition, uncleaved gp140 proteins form aggregates
post-purification, which probably arises from the inappro-
priate exposure of hydrophobic sites within gp41ECTO. The
native-like SOSIP.664 trimers do not form such aggregates.
The present cell lines were not made under GMP-
conditions, but their creation serves as a proof of concept
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serve as the sources of BG505 SOSIP.664 gp140 trimers
for human testing as vaccine antigens. CHO cell lines are
commonly employed to make clinical grade recombinant
proteins, and the use of 293 cell-based lines may also be
feasible. We have recently re-designed the present pAM/C
BG505 vector to facilitate the insertion of other env genes
and thereby increase its flexibility as a device to produce
SOSIP trimers based on a range of sequences. This vector
system is also useful for making Furin-cleaved SOSIP tri-
mers by transient transfection. We are presently assessing,
in rabbits, its utility as a DNA vaccine vector for express-
ing cleaved SOSIP trimers in vivo.
Conclusions
The stable CHO and 293 T cell lines yield non-degraded,
native-like BG505 SOSIP.664 trimers of an appropriate
quality for structural studies and animal immunogenicity
experiments. The creation of these cell lines also repre-
sents a proof of concept for the production of these tri-
mers under GMP conditions for human clinical trials.
Methods
Construct design
The BG505 SOSIP.664 gp140 env gene construct, based
on the HIV-1 subtype A transmitted/founder virus BG505,
has been described previously [10]. The gene was cloned
into an expression plasmid containing a Flp Recombin-
ation Target (FRT) site linked to the hygromycin resistance
gene, to permit Flp recombinase-mediated integration and
facilitate the selection of a stable cell line expressing gp140
under the control of the human cytomegalovirus (CMV)
immediate-early enhancer/promoter (Figure 1A). The furin
protease gene was inserted into the same expression vector
under the control of the EFI Alpha promoter. The resulting
vector expressing both the gp140 and Furin proteins was
termed pAM/C BG505. Large-scale plasmid preparations
were prepared by transformation of DH5α-competent cells
using a Qiagen™ EndoFree MaxiPrep kit according to the
manufacturer’s instructions.
Stable transfection of 293 T and CHO Flp-In™ cells
The Flp-In™ cells (293 T and CHO) were purchased from
Invitrogen. These cells contain a single integrated FRT
site and stably express the lacZ-Zeocin fusion gene. Par-
ental 293 T Flp-In™ and CHO Flp-In™ cells were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
or Ham’s F-12 Medium, respectively, supplemented with
10% heat-inactivated FBS (Sigma, St. Louis, MO, USA),
200 U/ml penicillin/streptomycin, 2 mM L-glutamine,
20 mM HEPES, 0.1 mM non-essential amino acids, 1 mM
sodium pyruvate (Gibco, Life Technologies, Carlsbad, CA,
USA), and further supplemented with 100 μg/ml Zeocin
(Invitrogen, Carlsbad, CA, USA).Prior to transfection, 5 × 105 cells were seeded into 6-
well plates in 2 ml complete medium; they were ~70-80%
confluent at the time of transfection. The pAM/C BG505
and pOG44 recombinase (Invitrogen, Carlsbad, CA, USA)
expression vectors, the latter mediating integration into the
FRT site of the Flp-In™ cells, were co-transfected using Li-
pofectamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions. Briefly, 0.5 μg of the
pAM/C BG505 and 4.5 μg of the pOG44 vectors (1:9 ratio)
in Opti-MEM reduced serum medium (Gibco Life Tech-
nologies, Carlsbad, CA, USA) were mixed with 15 μl of Li-
pofectamine for 45 min at room temperature. The DNA/
Lipofectamine complexes were then incubated with the cells
for 6 h before addition of 2 ml fresh complete medium
(without Zeocin). After culturing for a further 3 days, the
cells were harvested and seeded (1 × 106) into 100-mm Petri
dishes (Falcon, San Jose, CA, USA) in the continued pres-
ence of hygromycin (150 μg/ml for 293 T cells, 500 μg/ml
for CHO Flp-In™ cells). The selective medium was replen-
ished every 3–4 days until discrete foci of hygromycin-
resistant cells were evident after three weeks of selection.
Clone selection
After the tissue culture medium was completely removed, a
hydrophobic barrier was drawn around the hygromycin-
resistant foci with a Pap Pen (Abcam, Cambridge, UK) be-
fore addition of 200 μl of 2.5% trypsin-EDTA (Invitrogen,
Carlsbad, CA, USA). The released cells were harvested,
seeded into 48-well plates and expanded in the presence of
hygromycin. Cells were selected for further propagation
once they were verified to be both hygromycin-resistant
and to continually express HIV-1 Env, as assessed by dot
blotting every 4–5 days (see below). Limiting dilution was
performed according to recommendations in the manual
‘Corning Single Cell Cloning by Serial Dilution’. Briefly,
4000 cells were added to well A1 of a 96-well plate. Then,
using a single channel pipettor, a 100 μl aliquot was trans-
ferred from the first well to well B and mixed by gentle pip-
etting. The 1:2 dilutions were then repeated down the
entire column. Using an 8-channel micropipettor, an add-
itional 100 μl of medium was added to each well in column
1. Then, using the same pipettor, 100 μl of medium was
transferred from the wells in the first column (A1-H1) to
those in the second column (A2-H2) and mixed. Using the
same tips, the 1:2 dilutions were repeated across the entire
plate so that all wells finally contained 100 μl of cell suspen-
sion. After culturing for ~2.5 weeks, cells were selected for
subsequent expansion based on their rate of growth and
their constitutive, high level expression of secreted trimers
(as judged by ELISA; see below), or intracellular Env pro-
teins (as determined by flow cytometry or fluorescent mi-
croscopy; see below). To assess cell viability changes with
increasing passage number, we used the trypan blue exclu-
sion test (Life Technologies, Carlsbad, CA, USA).
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Briefly, 2 μl of culture supernatant from cells under hygro-
mycin selection were spotted onto nitrocellulose membrane
and allowed to air-dry for 10 min. The membrane was
blocked in 5% goat serum and incubated with MAb 2G12
(1:1000 dilution) for 1 h, followed by addition of biotinyl-
ated goat anti-human IgG (H + L) (1:2000 dilution) for
30 min. The membrane was then washed three times in
Tris-buffered saline containing 0.05% Tween 20, incubated
with VECTASTAIN® ABC Reagent (Vector Laboratories,
Burlingame, CA, USA) for 20 min, and again washed three
times in TBST before incubation with 3,3′,5,5′-Tetra-
methylbenzidine (TMB) substrate (Vector Laboratories,
Burlingame, CA, USA) until the blue color was developed.
Production of BG505 SOSIP.664 trimers and other Env
proteins by transient transfection
Large-scale expression of BG505 SOSIP.664 trimers was
performed using standard 293 T and CHO cells (see
Results). The cells were seeded into hyperflasks (Corning
Life Sciences, Union City, CA, USA) and transiently trans-
fected with the pAM/C BG505 vector using linear poly-
ethylenimine (PEI), as previously described [24]. Briefly,
600 μg of pAM/C BG505 was diluted in 60 ml of OPTI-
MEM to which 3 ml of PEI (final concentration, 1 mg/ml,
pH 7.5) was added drop-wise. After incubation for 20 min
at room temperature, the DNA-PEI mix was diluted in
500 ml of complete medium and added to the cells. The
supernatants were harvested 72 h after transfection and fil-
tered prior to purification of the trimers.
Monomeric MN gp120 was expressed in 293 T cells by
transient transfection using the MaxCyte electroporation
transfection system, and purified by immunoaffinity chro-
matography using a CD4-IgG2 column coupled to CnBr-
Sepharose (GE Healthcare, Fairfield, CT, USA). Briefly,
transfection supernatants were passed over the antibody col-
umn. After washing the proteins were eluted with high salt,
dialyzed into PBS and concentrated. The expression plasmid
was provided by the IAVI NAC Reagent Repository.
Uncleaved CZA97.012 gp140 was expressed in 293 T
cells by transient transfection via the PEI-based method
described above, using a plasmid provided by Bing Chen
(Harvard University). The resulting gp140 proteins contain
a C-terminal Foldon domain and a His-tag, and were iso-
lated on a Ni2+-column via their His-tags as described else-
where [20]. SEC was then used to purify the fraction
corresponding to three gp120 and three gp41ECTO subunits.
Purification of BG505 SOSIP.664 gp140 trimers
Trimers produced by the permanent cell lines or by transi-
ent transfection were purified as described elsewhere, with
some minor modifications [6,10,13,25]. Env proteins in cul-
ture supernatants were first enriched by affinity chromatog-
raphy on a Sepharose 4B column to which 2G12 (PolymunSciences, Klosterneuburg, Austria) had been attached by
CNBr-activation (GE Healthcare, Fairfield, CT, USA). The
column was washed with 15–20 column volumes of buffer
(500 mM NaCl, 10 mM Tris, pH 8.0) before Env proteins
were eluted with 3–5 column volumes of 3 M MgCl2. The
eluted Env proteins were immediately buffer exchanged into
75 mM NaCl, 10 mM Tris, pH 8.0 and then concentrated
using Vivaspin ultrafilters (100 kDa MWCO; GE Healthcare,
Fairfield, CT, USA). Trimers were separated from dimers
and monomers by SEC on a Superdex HiLoad column (GE
Healthcare, Fairfield, CT, USA). The trimer-containing frac-
tions were pooled and concentrated. Protein concentrations
were determined using a bicinchonic acid-based assay (BCA
assay; Thermo Scientific, Waltham, MA, USA).
SDS-page, blue native (BN)-page and western blotting
Env proteins were detected by SDS-PAGE, BN-PAGE and
Western blotting, as previously described [7,25]. Briefly,
Western blotting was performed after transfer of proteins
onto a nitrocellulose membrane (Invitrogen, Carlsbad, CA,
USA) at 32–40 V for 1–1.5 h. The membranes were
blocked with 10% goat serum for 1 h at room temperature
and incubated overnight with a 1:2000 dilution of the anti-
gp120 MAb ARP 3119 (obtained from the NIBSC Reagent
Repository), followed by a 1:5000 dilution of horseradish
peroxidase-conjugated goat anti-mouse IgG (H+ L) and
the Western Lightning plus-ECL Enhanced Luminol Re-
agent (Perkin Elmer, Waltham, MA, USA). Alternatively,
the membranes were probed with a HIV-Ig pool derived
from individuals infected with viruses from subtypes A, B
and C. The subtype A serum was obtained from Stephanie
Rainwater (The Fred Hutchinson Cancer Research Center),
the subtype C serum from Zdenek Hel (University of Ala-
bama, Birmingham), and the subtype B serum from the
AIDS Research and Reference Reagent Program (ARRRP)
(product #3957, lot 110180). Each individual serum was
present at a 1:3000 dilution in 10 ml of TBS + 0.05%
Tween-20. The detection antibody was a 1:3000 dilution
of biotin-conjugated goat anti-human IgG, followed by an
Avidin-Biotin-HRP complex and a peroxidase substrate
kit (all from Vector Laboratories, Burlingame, CA).
Detecting intracellular Env expression by flow cytometry
or fluorescent microscopy
We detected intracellular Env expression by using Fluor-
escein Isothiocyanate (FITC)-conjugated 2G12. To make
FITC-2G12, the MAb was equilibrated into a sodium
carbonate reaction buffer at pH 9.5 before FITC was added
at a 10-fold molar excess (over IgG) for 30 min with gentle
shaking. The mixture was fractionated using a Sephadex G-
25 column with PBS as the eluent. The FITC-conjugated
IgG concentration in the fractions (each 0.5 ml) was deter-
mined by measuring absorbance at 280 and 493 nm. The
fluorescein/IgG ratio in the final pool of FITC-2G12 was
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Stable transfectants or parental 293 T and CHO Flp-In™
cells were cultured for 6 h in the absence or presence of
Brefeldin A (1 μg/ml; GolgiPlug™ from BD Biosciences, San
Jose, CA, USA), which blocks the exit of excretory proteins
from the endoplasmic reticulum. The cells were harvested
after a brief treatment with trypsin-EDTA solution (2.5%
trypsin/2.21 mM EDTA; Corning Life Sciences, Union City,
CA, USA) and washed once in complete medium and twice
in PBS (centrifugation at 300 g). To prevent non-specific
binding of the detection MAb (i.e., FITC-2G12) to surface
antigens, the cells were re-suspended in 100 μl of FACS
buffer (PBS plus 2% FBS) and incubated with the “FcR
block” reagent (Miltenyi Biotec; 5 μl/test) for 20 min at 4°C
before addition of 250 μl of BD Fixation buffer (BD Biosci-
ences, San Jose, CA, USA) for 20 min at 4°C. Following fix-
ation, the cells were washed twice in 2 ml of Perm/Wash™
buffer (BD Biosciences, San Jose, CA, USA). To prevent
non-specific MAb binding to intracellular antigens, the
cells were further blocked with human AB serum (Sigma,
St. Louis, MO, USA; 5 μl in 100 μl Perm/Wash™ buffer) for
20 min at 4°C, before incubation with FITC-2G12 (20 μg/
ml) for a further 20 min at 4°C. Finally, the cells were
washed three times in 2 ml Perm/Wash™ buffer and ac-
quired using an LSR II FACS machine.
Alternatively, the 293 T and CHO cell clones were grown
in an 8-well chamber slide (Thermo Scientific, Waltham,
MA, USA) and treated with GolgiPlug™ (i.e., Brefeldin A)
for 6 h. The cells were then fixed with 300 μl of acetone
and methanol (1:1) at room temperature with gentle agita-
tion for 10 min, washed five times in PBS, stained with
FITC-2G12 (1:1000) for 1 h with agitation, and again
washed five times in PBS. After counterstaining for 5 min
with DAPI Nucleic Acid Stain (1:5000 dilution, Molecular
Probes, Eugene, OR, USA), the culture chamber was re-
moved using a slide separator and the slide mounted. Im-
ages were captured via a fluorescent microscope and digital
camera (DMI6000B; Leica, Solms, Germany).
Detecting BG505 SOSIP.664 gp140 trimers by ELISA
The ELISA to quantify the production of BG505 SOSIP.664
trimers by the cell lines was based on capturing Env pro-
teins to the solid phase via MAb 2G12, and detecting
trimers via biotin-labeled PGT145, a bNAb to a quater-
nary (i.e., trimer-dependent) epitope [21]. We also used
biotin-labeled MAb F105 to probe for the production of
undesired forms of Env, as the CD4-binding site (CD4bs)
epitope for this non-neutralizing antibody (non-NAb) is
inaccessible on native trimers but available on gp120 mono-
mers and uncleaved gp140s [6,10]. MAb 2G12 was pro-
vided by Hermann Katinger through the ARRRP; MAbs
PGT145 and F105 were provided by the IAVI Reagent Re-
pository via Steven Fling.For biotin conjugation, we used an EZ-Link Micro Sulfo-
NHS-Biotinylation Kit (Thermo Scientific, Waltham, MA,
USA). PGT145 or F105 (200 μg) was passed through a
Zebra™ Spin desalting column and incubated with Sulfo-
NHS-Biotin solution (11 mM) for 1 h at room temperature.
The mixture was passed through a desalting column to re-
move excess biotin. The collected flow-through solution
contains biotinylated MAb (bio-PGT145 or bio-F105) and
was stored at 4°C.
Trimer production in culture supernatants from 293 T
and CHO cell lines was assessed as follows. Briefly, Max-
isorp ELISA plates were coated with 2G12 at 1 μg/ml
overnight at 4°C (100 μl/well). The wells were washed
three times with PBS containing 0.05% Tween 20 (PBST),
and then blocked with PBS containing 2% non-fat milk for
1 h at room temperature. Culture supernatants were seri-
ally diluted and added to the wells for 2 h at room
temperature. After three washes with PBST, 100 μl of bio-
PGT145 or bio-F105 (1 μg/ml) was added for 1 h, before
washing 3 times with PBST and addition of poly-HRP
streptavidin (Thermo Scientific, Waltham, MA, USA;
1:2500 dilution in PBS containing 2% non-fat milk and
10% sheep serum) for a further 1 h. After a final 3 washes
in PBST, the colorimetric endpoint was generated using 1-
STEP Ultra TMB-ELISA substrate (Thermo Scientific,
Waltham, MA, USA). Absorbance was measured at
450 nm.
Assessing BG505 SOSIP.664 gp140 trimer antigenicity
by SPR
MAb binding to purified trimers at 25°C was detected
by surface plasmon resonance (SPR) with a Biacore 3000
instrument (GE Healthcare, Fairfield, CT, USA), essen-
tially using one of the methods described elsewhere [10].
Env-reactive MAbs were captured onto CM5 chips by
immobilized anti-Fc Ab, and the binding of solution-
phase trimers was recorded. Affinity-purified goat anti-
human IgG Fc (Bethyl Laboratories, Montgomery, TX,
USA) was diluted to 50 μg/ml in sodium acetate
(pH 4.5) and then amine-coupled to dextran, reaching
levels ~104 RU, in all four channels. MAbs were added at
1 μg/ml in running buffer (150 mM NaCl, 10 mM HEPES,
pH 7.4, 3 mM EDTA plus 0.005% Tween 20) to three
channels on each chip, at a flow rate of 5 μl/min, and cap-
tured to response level of 500–550 RU; a channel with
only anti-Fc served as a control surface. Trimers, at 200
nM in running buffer, were injected at a flow rate of
50 μl/min. Association was recorded for 300 s and dissoci-
ation for 600 s. Background signals obtained from the
control channel with trimer and from the test channel
without trimer were both subtracted. The anti-human
IgG-Fc surface was regenerated after each cycle by a single
injection of 10 mM Glycine (pH 1.5) for 120 s at a flow
rate of 30 μl/min.
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stain electron microscopy
SEC-purified trimers were analyzed by negative stain
EM as previously described [6,10]. A 3 μl aliquot con-
taining ~0.03 mg/ml of the trimer was applied for 5 s
onto a carbon-coated 400 Cu mesh grid that had been
glow discharged at 20 mA for 30 s, then negatively stained
with Uranyl formate for 30 s. Data were collected using a
FEI Tecnai T12 or T20 electron microscope operating at
120 keV, with an electron dose of ~55e−/Å2 and magnifi-
cations of 52,000× or 29,000×. Images were acquired with
a Tietz TemCam-F416 CMOS or Gatan US4000 camera
using a nominal defocus range of 900 to 1300 nm.
Differential scanning calorimetry
For thermal denaturation analysis, the 293 T and CHO cell-
derived trimers were SEC-purified in phosphate buffered
saline (PBS) before loading into the VP-differential scanning
calorimetry (DSC) calorimeter (GE Healthcare, Fairfield,
CT, USA). Thermal denaturation was conducted at a scan
rate of 90°C/h. Buffer correction, normalization and base-
line subtraction, and data analysis were conducted using
the Origin 7.0 software.
Abbreviations
BN-PAGE: Blue native-polyacrylamide gel electrophoresis; CD4bs: CD4-binding
site; DSC: Differential scanning calorimetry; Env: Envelope glycoprotein;
ELISA: Enzyme-linked immunosorbent assay; EM: Electron microscopy; FRT: Flp
Recombination Target; GMP: Good manufacturing practice; HIV: Human
immunodeficiency virus; HRP: Horseradish peroxidase; MAb: Monoclonal
antibody; NAb: Neutralizing antibody; SEC: Size-exclusion chromatography;
SPR: Surface plasmon resonance.
Competing interest
PJK, RWS, ABW, IAW, JPM and AC are listed on a patent application relating
to the general use of BG505 SOSIP.664 gp140 trimers. NPYC, KM, JPM, AM
and AC will be listed on a patent filing relating to the cell lines described in
this manuscript. The other authors have no competing interests to declare.
Authors’ contributions
AC, AM and JPM conceived the study. NPYC, KM, MG, KR and PJK developed
and analyzed the cell lines. TK developed and used the trimer ELISA. HJK,
IAW and ABW performed EM and DSC analyses. JK and AC purified and
characterized trimers. AY and PJK performed and analyzed SPR experiments.
AM and AC designed the pAM/C vector. NPYC, KM, AC and JPM wrote the
manuscript, with input from PJK, RWS, IAW and ABW. All authors read and
approved the final manuscript.
Acknowledgements
This work was supported by NIH HIVRAD grant P01 AI082362, the Scripps
CHAVI-ID (UM1 AI100663), the International AIDS Vaccine Initiative, a Vidi
grant from the Netherlands Organization for Scientific Research (R.W.S.), a
Starting Investigator Grant from the European Research Council (R.W.S.). We
thank Bing Chen (Harvard University) for the CZA97.012 gp140 plasmid, and
Zdenek Hel and Stephanie Rainwater for HIV-Ig preparations. We are grateful
to Rick King (IAVI) and Dennis Burton (Scripps) for helpful suggestions.
Author details
1Department of Microbiology and Immunology, Weill Cornell Medical
College, New York, NY, USA. 2Department of Integrative Structural and
Computational Biology, IAVI-Neutralizing Antibody Center, CHAVI-ID, The
Scripps Research Institute, La Jolla, California, USA. 3The Skaggs Institute for
Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.
4Department of Medical Microbiology, Academic Medical Center, Universityof Amsterdam, Amsterdam, The Netherlands. 5Current address: Alexion
Pharmaceuticals, Cheshire, Connecticut, USA. 6Current address: Innovimmune
Biotherapeutics, Inc, New York, NY, USA.
Received: 10 February 2014 Accepted: 27 March 2014
Published: 25 April 2014
References
1. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ,
Sordoski J, Wilson IA, Wyatt RT: HIV vaccine design and the neutralizing
antibody problem. Nat Immunol 2004, 5:233–236.
2. Zwick MB, Burton DR: HIV-1 neutralization: mechanisms and relevance to
vaccine design. Curr HIV Res 2007, 5:608–624.
3. Walker LM, Burton DR: Rational antibody-based HIV-1 vaccine design:
current approaches and future directions. Curr Opin Immunol 2010,
22:358–366.
4. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S: Molecular
architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109–113.
5. Guttman M, Lee KK: A functional interaction between gp41 and gp120 is
observed for monomeric but not oligomeric, uncleaved HIV-1 Env
gp140. J Virol 2013, 87:11462–11475.
6. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J,
Derking R, van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP:
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein
trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 2013,
110:18256–18261.
7. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R,
Paluch M, Berkhout B, Maddon PJ, Olson WC, Lu M, Moore JP: Stabilization
of the soluble, cleaved, trimeric form of the envelope glycoprotein
complex of human immunodeficiency virus type 1. J Virol 2002,
76:8875–8889.
8. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, Guo Y, Kajumo F,
Anselma DJ, Maddon PJ, Olson WC, Moore JP: A recombinant human
immunodeficiency virus type 1 envelope glycoprotein complex
stabilized by an intermolecular disulfide bond between the gp120 and
gp41 subunits is an antigenic mimic of the trimeric virion-associated
structure. J Virol 2000, 74:627–643.
9. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B,
Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP: Enhancing the
proteolytic maturation of human immunodeficiency virus type 1
envelope glycoproteins. J Virol 2002, 76:2606–2616.
10. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kin HJ,
Blattner C, de la Pena AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ,
van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP: A next-
generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140,
expresses multiple epitopes for broadly neutralizing but not non-
neutralizing antibodies. PLoS Pathog 2013, 9:e1003618.
11. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D,
Rainwater SM, Overbaugh J: Neutralization escape variants of human
immunodeficiency virus type 1 are transmitted from mother to infant.
J Virol 2006, 80:835–844.
12. Hoffenberg S, Powell R, Carpov A, Wagner D, Wilson A, Kosakovsky Pond S,
Lindsay R, Arendt H, Destefano J, Phogat S, Poignard P, Fling SP, Simek M,
Labranche C, Montefiori D, Wrin T, Phung P, Burton D, Koff W, King CR,
Parks CL, Caulfield MJ: Identification of an HIV-1 clade A envelope that
exhibits broad antigenicity and neutralization sensitivity and elicits
antibodies targeting three distinct epitopes. J Virol 2013, 87:5372–5383.
13. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ,
Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA: Crystal structure of
a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477–1483.
14. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR,
Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB: Cryo-EM Structure
of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science
2013, 342:1484–1490.
15. Lu H, Khurana S, Verma N, Manischewitz J, King L, Beigel JH, Golding H: A
rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin
vaccine immunogen in mammalian cells. PLoS One 2011, 6:e17297.
16. pcDNA™5/FRT Vector. Expression vector designed for use with the
Flp-In™ system. Invitrogen Instruction Manual, Ver. USA: Invitrogen; 2012:1–8
[http://tools.lifetechnologies.com/content/sfs/manuals/flpin_pcdna5frt_man.
pdf]
Chung et al. Retrovirology 2014, 11:33 Page 14 of 14
http://www.retrovirology.com/content/11/1/3317. Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR,
Parren PW, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC:
Oligomeric and conformational properties of a proteolytically mature,
disulfide-stabilized human immunodeficiency virus type 1 gp140
envelope glycoprotein. J Virol 2002, 76:7760–7776.
18. Schulz TF, Reeves JD, Hoad JG, Tailor C, Stephens P, Clements G, Ortlepp S,
Page KA, Moore JP, Weiss RA: Effect of mutations in the V3 loop of HIV-1
gp120 on infectivity and susceptibility to proteolytic cleavage. AIDS Res
Hum Retroviruses 1993, 9:159–166.
19. Clements GJ, Price-Jones MJ, Stephens PE, Sutton C, Schulz TF, Clapham PR,
McKeating JA, McClure MO, Thomson S, Marsh M, Kay J, Weiss RA, Moore JP: The
V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic
cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses
1991, 7:3–16.
20. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS,
Barouch DH, Chen B: HIV-1 envelope trimer elicits more potent
neutralizing antibody responses than monomeric gp120. Proc Natl Acad
Sci U S A 2012, 109:12111–12116.
21. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK,
Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA,
Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA,
Burton DR, Poignard P: Broad neutralization coverage of HIV by multiple
highly potent antibodies. Nature 2011, 477:466–470.
22. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, Caulifield MJ,
King CR, Marozsan AJ, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB:
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing
antibody PG9. Proc Natl Acad Sci U S A 2013, 110:4351–4356.
23. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC,
Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ,
Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA:
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding
via recognition of the HIV-1 gp120 V3 base and multiple surrounding
glycans. PLoS Pathog 2013, 9:e1003342.
24. Kirschner M, Monrose V, Paluch M, Techodamrongsin N, Rethwilm A, Moore JP:
The production of cleaved, trimeric human immunodeficiency virus type 1
(HIV-1) envelope glycoprotein vaccine antigens and infectious
pseudoviruses using linear polyethylenimine as a transfection reagent.
Protein Expr Purif 2006, 48:61–68.
25. Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, Katpally U, Cocco N,
Kachare M, Massi E, David KB, Cupo A, Marozsan AJ, Olson WC, Ward AB,
Wilson IA, Sanders RW, Moore JP: Partial enzymatic deglycosylation
preserves the structure of cleaved recombinant HIV-1 envelope
glycoprotein trimers. J Biol Chem 2012, 287:24239–24254.
doi:10.1186/1742-4690-11-33
Cite this article as: Chung et al.: Stable 293 T and CHO cell lines expressing
cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine
studies. Retrovirology 2014 11:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
